Relationship between HIV protease inhibitors and QTc interval duration in HIV-infected patients: A cross-sectional study

British Journal of Clinical Pharmacology

Volumn 67, Issue 1, 2009, Pages 76-82

  Charbit, Beny ^a,b,c   Rosier, Arnaud ^a,b,c   Bollens, Diane ^a,b   Boccara, Franck ^a,b   Boelle, Pierre Yves ^a,b,c   Koubaa, Afef ^a,b,c   Girard, Pierre Marie ^a,b   Funck Brentano, Christian ^a,b,c  

^a HÔPITAL SAINT ANTOINE   (France)

^b SORBONNE UNIVERSITÉ   (France)

^c INSERM   (France)

Author keywords

Electrocardiography; HIV infection; HIV protease inhibitors; Long QT syndrome

Indexed keywords

ABACAVIR; ATAZANAVIR; CHLOROQUINE; DOMPERIDONE; EFAVIRENZ; HALOPERIDOL; LAMIVUDINE; LOPINAVIR; METHADONE; MOXIFLOXACIN; NEVIRAPINE; POTASSIUM CHANNEL HERG; PROTEINASE INHIBITOR; RITONAVIR; TENOFOVIR;

ADULT; AGE; ARTICLE; BAZETT FORMULA; CONFIDENCE INTERVAL; CORRELATION ANALYSIS; DISEASE DURATION; DRUG EFFECT; ECG ABNORMALITY; ELECTROCARDIOGRAPHY; ETHNICITY; FEMALE; FRIDERICIA FORMULA; GENDER; HEART BUNDLE BRANCH BLOCK; HEART VENTRICLE HYPERTROPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VITRO STUDY; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MATHEMATICAL MODEL; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; QT INTERVAL; QT PROLONGATION; RISK FACTOR; STATISTICAL ANALYSIS; TORSADE DES POINTES;

ADULT; ARRHYTHMIAS, CARDIAC; CROSS-SECTIONAL STUDIES; ELECTROCARDIOGRAPHY; FEMALE; HEART RATE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; MALE; MIDDLE AGED; POTASSIUM; PROSPECTIVE STUDIES;

EID: 58149116616     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2008.03332.x     Document Type: Article

References (25)

1. Anson BD, Weaver JG, Ackerman MJ, Akinsete O, Henry K, January CT, Badley AD. Blockade of HERG channels by HIV protease inhibitors. Lancet 2005 365 : 682 6.
2. Busti AJ, Tsikouris JP, Peeters MJ, Das SR, Canham RM, Abdullah SM, Margolis DM. A prospective evaluation of the effect of atazanavir on the QTc interval and QTc dispersion in HIV-positive patients. HIV Med 2006 7 : 317 22.
3. Bednar MM, Harrigan EP, Anziano RJ, Camm AJ, Ruskin JN. The QT interval. Prog Cardiovasc Dis 2001 43 : 1 45.
4. Bernardi M, Calandra S, Colantoni A, Trevisani F, Raimondo ML, Sica G, Schepis F, Mandini M, Simoni P, Contin M, Raimondo G. QT interval prolongation in cirrhosis: prevalence, relationship with severity, and etiology of the disease and possible pathogenetic factors. Hepatology 1998 27 : 28 34.
5. Schillaci G, Pirro M, Ronti T, Gemelli F, Pucci G, Innocente S, Porcellati C, Mannarino E. Prognostic impact of prolonged ventricular repolarization in hypertension. Arch Intern Med 2006 166 : 909 13.
6. Okin PM, Devereux RB, Lee ET, Galloway JM, Howard BV. Electrocardiographic repolarization complexity and abnormality predict all-cause and cardiovascular mortality in diabetes: the strong heart study. Diabetes 2004 53 : 434 40.
7. Villa A, Foresti V, Confalonieri F. Autonomic neuropathy and prolongation of QT interval in human immunodeficiency virus infection. Clin Auton Res 1995 5 : 48 52.
8. Kocheril AG, Bokhari SA, Batsford WP, Sinusas AJ. Long QTc and torsades de pointes in human immunodeficiency virus disease. Pacing Clin Electrophysiol 1997 20 : 2810 6.
9. Nordin C, Kohli A, Beca S, Zaharia V, Grant T, Leider J, Marantz P. Importance of hepatitis C coinfection in the development of QT prolongation in HIV-infected patients. J Electrocardiol 2006 39 : 199 205.
10. Sudano I, Spieker LE, Noll G, Corti R, Weber R, Luscher TF. Cardiovascular disease in HIV infection. Am Heart J 2006 151 : 1147 55.
11. Malik M. Problems of heart rate correction in assessment of drug-induced QT interval prolongation. J Cardiovasc Electrophysiol 2001 12 : 411 20.
12. Grandinetti A, Seifried S, Mor J, Chang HK, Theriault AG. Prevalence and risk factors for prolonged QTc in a multiethnic cohort in rural Hawaii. Clin Biochem 2005 38 : 116 22.
13. Benoit SR, Mendelsohn AB, Nourjah P, Staffa JA, Graham DJ. Risk factors for prolonged QTc among US adults: Third National Health and Nutrition Examination Survey. Eur J Cardiovasc Prev Rehabil 2005 12 : 363 8.
14. Rodriguez I, Kilborn MJ, Liu XK, Pezzullo JC, Woosley RL. Drug-induced QT prolongation in women during the menstrual cycle. JAMA 2001 285 : 1322 6.
15. Vitelli LL, Crow RS, Shahar E, Hutchinson RG, Rautaharju PM, Folsom AR. Electrocardiographic findings in a healthy biracial population. Atherosclerosis Risk in Communities (ARIC) Study Investigators. Am J Cardiol 1998 81 : 453 9.
16. Becker K, Gorlach I, Frieling T, Haussinger D. Characterization and natural course of cardiac autonomic nervous dysfunction in HIV-infected patients. AIDS 1997 11 : 751 7.
17. Mittal CM, Wig N, Mishra S, Deepak KK. Heart rate variability in human immunodeficiency virus-positive individuals. Int J Cardiol 2004 94 : 1 6.
18. Fliers E, Sauerwein HP, Romijn JA, Reiss P, van der Valk M, Kalsbeek A, Kreier F, Buijs RM. HIV-associated adipose redistribution syndrome as a selective autonomic neuropathy. Lancet 2003 362 : 1758 60.
19. Robbins J, Nelson JC, Rautaharju PM, Gottdiener JS. The association between the length of the QT interval and mortality in the Cardiovascular Health Study. Am J Med 2003 115 : 689 94.
20. Goldberg RJ, Bengtson J, Chen Z, Anderson KM, Locati E, Levy D. Duration of the QT Interval and Total and Cardiovascular Mortality in Healthy Persons (the Framingham Heart Study Experience). Am J Cardiol 1991 67 : 55 8.
21. Karjalainen J, Reunanen A, Ristola P, Viitasalo M. QT interval as a cardiac risk factor in a middle aged population. Heart 1997 77 : 543 8.
22. Committee for Medicinal Products for Human Use. CHMP/ICH/2/04. The clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs, November 2005. Available at http://www.emea. europa.eu/pdfs/human/ich/000204en.pdf (last accessed 26 June 2008).
23. van Heeswijk RP, Bourbeau M, Seguin I, Giguere P, Garber GE, Cameron DW. Absence of circadian variation in the pharmacokinetics of lopinavir/ritonavir given as a once daily dosing regimen in HIV-1-infected patients. Br J Clin Pharmacol 2005 59 : 398 404.
24. Boffito M, Hoggard PG, Lindup WE, Bonora S, Sinicco A, Khoo SH, Di Perri G, Back DJ. Lopinavir protein binding in vivo through the 12-hour dosing interval. Ther Drug Monit 2004 26 : 35 9.
25. Jonker DM, Kenna LA, Leishman D, Wallis R, Milligan PA, Jonsson EN. A pharmacokinetic-pharmacodynamic model for the quantitative prediction of dofetilide clinical QT prolongation from human ether-a-go-go-related gene current inhibition data. Clin Pharmacol Ther 2005 77 : 572 82.